Prospects in treatment of multiple sclerosis: near future

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Multiple sclerosis (MS) is a widespread dysimmune-neurodegenerative disease of the central nervous system of unclear etiology. Despite significant achievements in the therapy of MS, the level of progressing disability and early mortality remains alarmingly high. The main aim of the given review is to give a detailed description of new promising medical drugs for treatment of MS. In the article the data of preclinical and clinical trials are given, presumptive mechanisms of the medical drugs under development are described. Development of new therapeutic approaches in treatment of MS is of great interest in modern science. The given review highlights new methods of treatment that are now undergoing clinical trialы and will probably come to the clinical practice in the near future.

Full Text

Restricted Access

About the authors

Gennadii E. Sheiko

Privolzhsk Research Medical University

Author for correspondence.
Email: sheikogennadii@yandex.ru
ORCID iD: 0000-0003-0402-7430
SPIN-code: 8575-1319

MD, PhD, Assistant of the Department of Medical Rehabilitation

Russian Federation, Nizhny Novgorod

Anna N. Belova

Privolzhsk Research Medical University

Email: anbelova@mail.ru
ORCID iD: 0000-0001-9719-6772
SPIN-code: 3084-3096
ResearcherId: T-2048-2019

MD, PhD, Professor, Head of the Department of Medical Rehabilitation

Russian Federation, Nizhny Novgorod

Maksim N. Kudykin

Balakhna Central Regional Hospital

Email: mady5@yandex.ru
ORCID iD: 0000-0002-2272-5331
SPIN-code: 2976-8060
ResearcherId: T-3302-2020

MD, PhD, Chief Physician

Russian Federation, Balakhna

References

  1. Shmidt TE, Yakhno NN. Rasseyannyy skleroz: rukovodstvo dlya vrachey. 6th ed. Moscow: MEDpress-inform; 2017. (In Russ).
  2. Mohammed EM. Multiple sclerosis is prominent in the Gulf states: Review. Pathogenesis. 2016;3(2): 19-38. doi: 10.1016/j.pathog.2016.04.001
  3. Gasperoni F, Turini P, Agostinelli E. A novel comprehensive paradigm for the etiopathogenesis of multiple sclerosis: therapeutic approaches and future perspectives on its treatment. Amino Acids. 2019; 51(5):745-59. doi: 10.1007/s00726-019-02718-1
  4. Filippi M, Preziosa P, Rocca MA. Multiple sclerosis. Handb Clin Neurol. 2016;135:399-423. doi: 10.1016/B978-0-444-53485-9.00020-9
  5. Alifirova VM, Bisaga GN, Boyko AN, et al. Clinical recommendations on the use of alemtuzumab (lemtrada). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):115-26. (In Russ). doi:10. 17116/jnevro201711722115-126
  6. Milo R. Therapies for multiple sclerosis targeting B cells. Croatian Medical Journal. 2019;60(2):87-98. doi: 10.3325/cmj.2019.60.87
  7. Ineichen BV, Moridi T, Granberg T, et al. Rituximab treatment for multiple sclerosis. Multiple Sclerosis Journal. 2020;26(2):137-52. doi:10.1177/ 1352458519858604
  8. Votintseva MV, Petrov AM, Stolyarov ID. Monoclonal antibodies: present and future in the treatment of multiple sclerosis (Based on the Proceedings of the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis – ECTRIMS). Annals of Clinical and Experimental Neurology. 2017;11(2):83-8. (In Russ). doi:10.18454 /ACEN.2017.2.12
  9. Cree B, Lamb S, Chin A, et al. Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology. 2004;62(Suppl. 5):A492.
  10. Hauser SL, Waubant E, Arnold DL, et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. The New England Journal of Medicine. 2008;358(7):676-88. doi: 10.1056/NEJMoa0706383
  11. Vartzelis G, Maritsi D, Nikolaidou M, et al. Rituximab as rescue therapy for aggressive pediatric multiple sclerosis. Case Reports in Pediatrics. 2019; 2019:8731613. doi: 10.1155/2019/8731613
  12. Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20): 2074-81. doi: 10.1212/WNL.0000000000003331
  13. Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 2019;18(9):845-56. doi: 10.1016/s1474-4422(19)30137-1
  14. Franks SE, Getahun A, Hogarth PM, et al. Targeting B cells in treatment of autoimmunity. Current Opinion in Immunology. 2016;43:39-45. doi: 10.1016/j.coi. 2016.09.003
  15. Bar-Or A, Grove RA., Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology. 2018;90(20):e1805-14. doi: 10.1212/WNL.0000000 000005516
  16. Derfuss T, Curtin F, Guebelin C, et al. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal. 2014;21(7):885-93. doi: 10.1177/1352458514554052
  17. Gusev EI, Guseva AB, editors. Bolezni nervnoy sistemy: mekhanizmy razvitiya, diagnostika i lecheniye. Moscow: Buki-Vedi; 2017. (In Russ).
  18. Ciotti JR, Cross AH. Disease-Modifying Treatment in Progressive Multiple Sclerosis. Current Treatment Options in Neurology. 2018;20(5):12. doi: 10.1007/s11940-018-0496-3
  19. Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology. 2017;176(3):412-20. doi:10.1111/ bjh.14447
  20. Fox E, Lovett-Racke A, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Multiple Sclerosis Journal. 2020;1352458520918375. doi: 10.1177/1352458520918375
  21. Boyko OV, Boyko AN, Yakovlev PA, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):87-95. (In Russ). doi: 10.17116/jnevro20191191087
  22. Alankus Y, Grenningloh R, Haselmayer P, et al. BTK inhibition prevents inflammatory macrophage differentiation: a potential role in MS. Multiple Sclerosis Journal. 2018;24:264.
  23. Montalban X, Arnold DL, Weber MS, et al.; Evobrutinib Phase 2 Study Group. Primary analysis of a randomised, placebocontrolled, phase 2 study of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal. 2018;24:984-5.
  24. Rafei M, Galipeau J. A chimeric cytokine to help autoimmune diseases. Medicine Science. 2010;26(2): 137-9. doi: 10.1051/medsci/2010262137
  25. Pennati A, Deng J, Galipeau J. Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives. PLoS One. 2014;9(9):e106724. doi:10. 1371/journal.pone.0106724
  26. Pouzol L, Piali L, Bernard CCA, et al. Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis. Innovations in Clinical Neuroscience. 2019;16(3-4):22-30.
  27. Dash RP, Rais R, Srinivas NR. Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. Xenobiotica. 2018; 48(5):442-51. doi: 10.1080/00498254.2017.1329568
  28. Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet Neurology. 2019;18(11):1009-20. doi: 10.1016/S1474-4422(19)30239-X
  29. Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. The Lancet Neurology. 2019;18(11):1021-33. doi:10.1016/ S1474-4422(19)30238-8
  30. Rasche L, Paul F. Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 2018;19(18):2073-86. doi:10. 1080/14656566.2018.1540592
  31. Fox RJ, Coffey CS, Conwit R et al. Phase 2 trial of Ibudilast in progressive multiple sclerosis. The New England Journal of Medicine. 2018;379(9):846-55. doi: 10.1056/NEJMoa1803583
  32. Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurology. 2012;12:36. doi: 10.1186/1471-2377-12-36
  33. Patti F, Fermo SL. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Diseases. 2011;2011:961702. doi:10. 4061/2011/961702
  34. Brochet B, Deloire MSA, Perez P, et al. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS One. 2017;12(1): e0168834. doi: 10.1371/journal.pone.0168834
  35. Cuascut FX, Hutton GJ. Stem cell-based therapies for multiple sclerosis: current perspectives. Biomedicines. 2019;7(2):e26. doi: 10.3390/biomedicines7020026
  36. Thiruvalluvan A, Czepiel M, Kap YA, et al. Survival and Functionality of Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis. Stem Cells Translational Medicine. 2016;5(11):1550-61. doi: 10.5966/sctm.2016-0024
  37. Delemarre EM, van den Broek T, Mijnheer G, et al. Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood. 2016;127(1): 91-101. doi: 10.1182/blood-2015-06-649145
  38. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9): 842-52. doi: 10.1212/WNL.0000000000003660
  39. Atkins HL, Bowman M, Allan D, et al. Immuno-ablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: а multicentre single-group phase 2 trial. The Lancet. 2016;388 (10044):576-85. doi: 10.1016/S0140-6736(16)30169-6
  40. Dahbour S, Jamali F, Alhattab D, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neuroscience & Therapeutics. 2017;23(11):866-74. doi: 10.1111/cns.12759

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies